- About Us
- Services & Solutions
- Technologies
- Discovery
- Reagent Materials Generation
- Monoclonal Antibody Discovery
- Bispecific & Multispecific Antibody Generation
- Lead Optimization
- In Vitro Lead Characterization
- In Vivo Lead Characterization
- Other Molecular Modalities
- IND Filing Support
- Protein Sciences
- Protein Production
- Protein Analytics
- Bioinformatics
- Protein Sciences
- Mammalian
- Microbial
- mRNA
- Viral Vaccines
- WuXi XDC – Bioconjugation
- Testing
- Sustainability
- Careers
- Investors
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- SustainabilityAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & ResourcesAbout Us
Newsletter: March 2020
A Message from Chris Chen, CEO WuXi Biologics
Chris Chen, Ph.D. and CEO of WuXi Biologics provides the industry with a best practices document from the lessons we learned in China while dealing with the COVID-19 outbreak. Included in his message is a note explaining that because we are fully back to work, we can help keep your mission-critical projects and R&D moving forward.
Just ask us how we can assist during these difficult times
Facilities and Operations
Click here to view a 60 second time-lapse video of construction progress at our new site in Dundalk, Ireland
WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany Read More
COVID-19 / Coronavirus Response
Dr. Chris Chen Ph.D., CEO WuXi Biologics, on panel for special on-line forum providing updates on diagnostic, therapeutic and vaccine developments for COVID-19/Coronavirus outbreak View On-Demand Webinar
WuXi Biologics Provides Back-to-work Operation Update Related to the Coronavirus Outbreak Read More
WuXi Biologics & Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19 Read More
WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus Read More
Partner News
WuXi Biologics’ Subsidiary WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader Read More
WuXi Biologics Congratulates Immutep on Positive Interim data for IMP-321 Read More
WuXi Biologics Congratulates OncoImmune on FDA Clearance of IND Application for Next Generation anti-CTLA-4 Antibody ONC-392 Read More
WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development Read More
WuXiBody™ Bispecific Antibody News
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases Read More
New Flexible Bispecific Antibody Format Demonstrates Improved Therapeutic Properties And Manufacturability Read More
WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics Read More
I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs Read More
Resources
From Concept to Market – Unique approaches in Biomanufacturing (Webinar)
Advanced Process Development Using Automated Micro Bioreactors Shortens Timelines & Provides Process Solutions for a Rapid Scale Up (Webinar)
Scale-Out Plus Single-Use Can Multiply Yields (Article)
Capacity Strategies: The Strategies Behind Choosing Between Large-Scale and Single-Use Investments (Article)
Viral Safety in Biomanufacturing (Video)
Ask the Expert Continuous Manufacturing (Article)
Scale-Out vs. Scale-Up GMP Manufacturing (Article)
WuXi Biologics Publications (Archive)
WuXi Biologics Perspectives (Archive)
Awards and Achievements
WuXi Biologics standardizes a remarkable 12 month “DNA to IND” timeline through its streamlined development platform Read More
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?